EquasensCHIX:EQSP 85 Net Margin % is 18.28% as of Dec. 2025, which is 2% above its 10-year median of 17.89. GuruFocus rates CHIX:EQSP with a GF Score™ of 85/100 and a GF Value™ of €50.68 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Equasens ranks better than 90.42% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Equasens's Net Income for the
six
months ended in Dec. 2025 was €22.0 Mil. Equasens's Revenue for the
six
months ended in Dec. 2025 was €120.5 Mil. Therefore, Equasens's net margin for the quarter that ended in Dec. 2025 was 18.28%.
The historical rank and industry rank for Equasens's Net Margin % or its related term are showing as below:
CHIX:EQSp'
s Net Margin % Range Over the Past 10 Years
Min: 16.02 Med: 17.89 Max: 21.66
Current: 16.63
CHIX:EQSp's Net Margin % is ranked better than 90.42% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs CHIX:EQSp: 16.63
Equasens (CHIX:EQSp) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Equasens Net Margin % Related Terms
Equasens Net Margin % Historical Data
* Premium members only.
The historical data trend for Equasens's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:EQSP vs VEEV, BTSG, TEM: Net Margin % Comparison
For the Health Information Services subindustry, Equasens's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equasens Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Equasens's Net Margin % distribution charts can be found below:
* The bar in red indicates where Equasens's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equasens (CHIX:EQSP) has a Net Margin % of 18.28% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Equasens and its competitors. This is near median its historical median of 17.89. Over the past decade, Equasens' Net Margin % has ranged from 16.02 to 21.66. According to the industry distribution chart, Equasens ranks #64 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 9.6%.
Is Equasens' Net Margin % too high?
Equasens' current Net Margin % of 18.28% is near median its 10-year median of 17.89. Over the past 10 years, this metric has ranged from a low of 16.02 to a high of 21.66. The Healthcare Providers & Services industry median Net Margin % is 2.89. Equasens' value of 18.28% is 533.6% above this industry median. Based on the distribution chart, Equasens ranks #64 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Equasens has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Equasens' Net Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Equasens ranks #64 out of 668 companies for Net Margin %. This places Equasens in the top 10% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.89. Equasens' value of 18.28% is 533.6% above this benchmark. Historically, Equasens' own Net Margin % has ranged from 16.02 to 21.66 over the past decade. While the company's 10-year median is 17.89 vs. the industry median of 2.89, Equasens has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current Net Margin % of 18.28% is 533.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Equasens and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current Net Margin % is 18.28%, which is near median its own 10-year median of 17.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Based on GuruFocus' analysis, Equasens (CHIX:EQSP) is currently considered Modestly Undervalued. The stock's GF Value™ is €50.68, compared to a current price of €38.48 — trading 24.1% below its estimated fair value. The current Net Margin % is 18.28%, which is near median its 10-year median of 17.89 and 533.6% above the Healthcare Providers & Services industry median of 2.89. Equasens' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Equasens (CHIX:EQSP), the current Net Margin % is 18.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Equasens (CHIX:EQSP) Overvalued in 2026?
Based on GuruFocus' analysis, Equasens stock appears to be undervalued.
The current stock price of €38.48 is trading 24.1% below its estimated GF Value™ of €50.68.
GuruFocus considers Equasens to be Modestly Undervalued.
Key valuation signals for CHIX:EQSP:
Net Margin %: 18.28% (near median its 10-year median of 17.89)
GF Value™: €50.68 vs. price of €38.48 (24.1% below fair value)
Industry Position: 533.6% above the Healthcare Providers & Services median (#64 of 668)
No single metric tells the full story. See the CHIX:EQSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
85GF Score
Get the complete analysis for CHIX:EQSP
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:EQSP has been successfully added to your 
